Narsingam Saiprasad, Bozarth Andrew L, Abdeljalil Asem
a 1 Department of Internal Medicine, University of Missouri-Kansas City School of Medicine , Kansas City, MO, USA.
Postgrad Med. 2015;127(7):758-70. doi: 10.1080/00325481.2015.1084212. Epub 2015 Sep 2.
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease state characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory process. It is increasingly recognized as a major public health problem, affecting more than 20 million adults in the US. It is also recognized as a leading cause of hospitalizations and is the fourth leading cause of death in the US. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) operates to promote evidence-based management of COPD, increase awareness and encourage research. In 2011, GOLD published a consensus report detailing evidence-based management strategies for COPD, which were last updated in 2015. In recent years, newer strategies and a growing number of new pharmacologic agents to treat symptoms of COPD have also been introduced and show promise in improving the management of COPD. We aim to provide an evidence-based review of the available and upcoming pharmacologic and non-pharmacologic treatment options for stable COPD, with continued emphasis on evidence-based management.
慢性阻塞性肺疾病（COPD）是一种可预防和可治疗的疾病状态，其特征为持续存在气流受限，通常呈进行性发展，并伴有慢性炎症过程增强。它日益被视为一个重大的公共卫生问题，在美国影响着超过2000万成年人。它也被认为是住院治疗的主要原因，并且是美国第四大死因。慢性阻塞性肺疾病全球倡议组织（GOLD）致力于促进基于证据的COPD管理，提高认识并鼓励开展研究。2011年，GOLD发布了一份共识报告，详细阐述了基于证据的COPD管理策略，该报告于2015年进行了最后更新。近年来，还引入了更新的策略以及越来越多用于治疗COPD症状的新型药物，这些药物在改善COPD管理方面显示出前景。我们旨在对稳定期COPD可用的以及即将出现的药物和非药物治疗选择进行基于证据的综述，并持续强调基于证据的管理。
